EpiCast Report: Head and Neck Cancers - Epidemiology Forecast to 2024

Description: EpiCast Report: Head and Neck Cancers - Epidemiology Forecast to 2024

Summary

Head and neck cancers (HNCs) are a heterogeneous group, consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth; the salivary glands; the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx; the nose, sinuses, and related structures; the larynx; and the thyroid. HNCs usually begin in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck — more than 80% of all HNCs are squamous cell carcinomas. HNCs are common in several regions across the globe and account for 600,000 new cases annually worldwide.

Our epidemiologists forecast an increase in diagnosed incident cases of HNCs in the 7MM from 151,393 diagnosed incident cases in 2014 to 174,056 diagnosed incident cases in 2024, with an Annual Growth Rate (AGR) of 1.50% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of HNCs in the 7MM, with 65,663 diagnosed incident cases, whereas the UK will have the lowest number of diagnosed incident cases of HNCs, with 12,702 diagnosed incident cases in 2024. The diagnosed incident cases of thyroid cancer in the 7MM are expected to increase from 93,225 diagnosed incident cases in 2014 to 123,504 diagnosed incident cases in 2024, with an AGR of 3.25% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of thyroid cancer in the 7MM with 81,286 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of thyroid cancer with 3,233 diagnosed incident cases in 2024.

Scope

- The Head and neck cancers (HNCs) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for HNCs in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases of HNCs segmented into three sub-groups: cancers of the lip, oral cavity, and pharynx; cancers of the nose, sinuses, and related structures; and cancers of the larynx, in these markets. It also includes a 10-year epidemiological forecast for the five-year diagnosed prevalent cases of HNCs (excluding nose, sinuses, and related cancers). Additionally, it includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of thyroid cancer in the 7MM. The diagnosed incident cases of HNCs (excluding nose, sinuses, and related cancers) and thyroid cancer are segmented by age, sex, clinical stage at diagnosis, and histology.
- The HNCs epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The HNCs EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global HNCs market.
- Quantify patient populations in the global HNCs market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HNCs therapeutics in each of the markets covered.

Contents:

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global Trends
3.3.1 Incidence
3.3.2 Relative Survival - 7MM
3.4 Forecast Methodology
3.4.1 Sources Used
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for HNCs and Thyroid Cancer (2014-2024)
3.5.1 Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer
3.5.2 Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers
3.5.3 Diagnosed Incident Cases of Larynx Cancer
3.5.4 Diagnosed Incident Cases of HNCs
3.5.5 Diagnosed Incident Cases of Thyroid Cancer
3.5.6 Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer
3.5.7 Age-Specific Diagnosed Incident Cases of Larynx Cancer
3.5.8 Age-Specific Diagnosed Incident Cases of Thyroid Cancer
3.5.9 Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer
3.5.10 Sex-Specific Diagnosed Incident Cases of Larynx Cancer
3.5.11 Sex-Specific Diagnosed Incident Cases of Thyroid Cancer
3.5.12 Age-Standardized Diagnosed Incidence of Lip, Oral Cavity, and Pharynx Cancer
3.5.13 Age-Standardized Diagnosed Incidence of Larynx Cancer
3.5.14 Age-Standardized Diagnosed Incidence of Thyroid Cancer
3.5.15 Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Clinical Stage at Diagnosis
3.5.16 Diagnosed Incident Cases of Larynx Cancer by Clinical Stage at Diagnosis
3.5.17 Diagnosed Incident Cases of Thyroid Cancer by Clinical Stage at Diagnosis
3.5.18 Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Histology Distribution
3.5.19 Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers by Histology Distribution
3.5.20 Diagnosed Incident Cases of Larynx Cancer by Histology Distribution
3.5.21 Diagnosed Incident Cases of Thyroid Cancer by Histology Distribution
3.5.22 Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer
3.5.23 Five-Year Diagnosed Prevalent Cases of Larynx Cancer
3.5.24 Five-Year Diagnosed Prevalent Cases of Thyroid Cancer

3.6 Discussion

3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologists
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head of Healthcare
4.3 About Us
4.4 About EpiCast
4.5 Disclaimer

1.1 List of Tables

Table 1: HNCs Clinical Stages at Diagnosis
Table 2: Risk Factors for HNCs
Table 3: Trends in the Age-Adjusted Incidence of Lip, Oral Cavity, and Pharynx Cancer in the 7MM, All Ages, 1998-2007
Table 4: Trends in the Age-Adjusted Incidence of Larynx Cancer in the 7MM, All Ages, 1998-2007
Table 5: Trends in the Age-Adjusted Incidence of Thyroid Cancer in the 7MM, All Ages, 1998-2007
Table 6: Trends in the Five-Year Relative Survival (%) of HNCs and Thyroid Cancer in the 7MM, Both Sexes, 1993-2007
Table 7: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer
Table 8: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Larynx Cancer
Table 9: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer

Table 10: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Thyroid Cancer

Table 11: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer

Table 12: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Larynx Cancer

Table 13: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Thyroid Cancer

Table 14: 7MM, Sources of Epidemiological Data Used for the Segmentation of Diagnosed Incident Cases of HNCs (Excluding Nose, Sinuses, and Related Cancers) and Thyroid Cancer by Clinical Stage at Diagnosis

Table 15: 7MM, Sources of Epidemiological Data Used for the Segmentation of the Diagnosed Incident Cases HNCs and Thyroid Cancer by Histology Distribution

Table 16: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, All Ages, N, 2014-2024

Table 17: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer, Both Sexes, All Ages, N, 2014-2024

Table 18: 7MM, Diagnosed Incident Cases of Larynx Cancer, Both Sexes, All Ages, N, 2014-2024

Table 19: 7MM, Diagnosed Incident Cases of HNCs, Both Sexes, All Ages, N, 2014-2024

Table 20: 7MM, Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, All Ages, N, 2014-2024

Table 21: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, N (Row %), 2014

Table 22: 7MM, Age-Specific Diagnosed Incident Cases of Larynx Cancer, Both Sexes, N (Row %), 2014

Table 23: 7MM, Age-Specific Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, N (Row %), 2014

Table 24: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, N (Row %), 2014

Table 25: 7MM, Sex-Specific Diagnosed Incident Cases of Larynx Cancer, All Ages, N (Row %), 2014

Table 26: 7MM, Sex-Specific Diagnosed Incident Cases of Thyroid Cancer, All Ages, N (Row %), 2014

Table 27: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, Both Sexes, N, 2014-2024

Table 28: 7MM, Five-Year Diagnosed Prevalent Cases of Larynx Cancer, All Ages, Both Sexes, N, 2014-2024

Table 29: 7MM, Five-Year Diagnosed Prevalent Cases of Thyroid Cancer, All Ages, Both Sexes, N, 2014-2024

1.2 List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, All Ages, N, 2014-2024

Figure 2: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer, Both Sexes, All Ages, N, 2014-2024

Figure 3: 7MM, Diagnosed Incident Cases of Larynx Cancer, Both Sexes, All Ages, N, 2014-2024
Figure 4: 7MM, Diagnosed Incident Cases of HNCs, Both Sexes, All Ages, N, 2014-2024

Figure 5: 7MM, Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, All Ages, N, 2014-2024

Figure 6: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, N, 2014

Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of Larynx Cancer, Both Sexes, N, 2014

Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, N, 2014

Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, N, 2014

Figure 10: 7MM, Sex-Specific Diagnosed Incident Cases of Larynx Cancer, All Ages, N, 2014

Figure 11: 7MM, Sex-Specific Diagnosed Incident Cases of Thyroid Cancer, All Ages, N, 2014

Figure 12: 7MM, Age-Standardized Diagnosed Incidence Cases of Lip, Oral Cavity, and Pharynx Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014

Figure 13: 7MM, Age-Standardized Diagnosed Incidence Cases of Larynx Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014

Figure 14: 7MM, Age-Standardized Diagnosed Incidence Cases of Thyroid Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014

Figure 15: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014

Figure 16: 7MM, Diagnosed Incident Cases of Larynx Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014

Figure 17: 7MM, Diagnosed Incident Cases of Thyroid Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014

Figure 18: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014

Figure 19: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers by Histology Distribution, All Ages, Both Sexes, N, 2014

Figure 20: 7MM, Diagnosed Incident Cases of Larynx Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014

Figure 21: 7MM, Diagnosed Incident Cases of Thyroid Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014

Figure 22: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, Both Sexes, N, 2014-2024

Figure 23: 7MM, Five-Year Diagnosed Prevalent Cases of Larynx Cancer, All Ages, Both Sexes, N, 2014-2024

Figure 24: 7MM, Five-Year Diagnosed Prevalent Cases of Thyroid Cancer, All Ages, Both Sexes, N, 2014-2024

Order by Fax - using the form below
Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: EpiCast Report: Head and Neck Cancers - Epidemiology Forecast to 2024
Web Address: http://www.researchandmarkets.com/reports/3622913/
Office Code: SCD2ST9K

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 3995</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>USD 7990</td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>USD 11985</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________________________ Last Name: ________________________________________
Email Address: * ________________________________________
Job Title: _____________________________________________________________________________________________
Organisation: _______________________________________________________________________________________  
Address: ___________________________________________________________________________________________
City: _____________________________________________________________________________________________  
Postal / Zip Code: ___________________________________________________________________________________
Country: __________________________________________________________________________________________
Phone Number: _____________________________________________________________________________________  
Fax Number: _______________________________________________________________________________________  

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB9853083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World